Nuveen
SYRE icon

Nuveen’s Spyre Therapeutics SYRE Stock Holding History

Nuveen’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1M Buy
181,105
+27,206
+18% +$1.99M ﹤0.01% 1406
2026
Q1 		$7.76M Buy
153,899
+2,919
+2% +$110K ﹤0.01% 1693
2025
Q4 		$4.95M Buy
150,980
+54,808
+57% +$1.43M ﹤0.01% 1913
2025
Q3 		$1.61M Sell
96,172
-38,896
-29% -$634K ﹤0.01% 2387
2025
Q2 		$2.02M Sell
135,068
-5,061
-4% -$74.9K ﹤0.01% 2293
2025
Q1 		$2.26M Buy
140,129
+14,461
+12% +$301K ﹤0.01% 2292
2024
Q4 		$2.93M Buy
125,668
+378
+0.3% +$11.1K ﹤0.01% 2225
2024
Q3 		$3.68M Buy
125,290
+8,150
+7% +$227K ﹤0.01% 2128
2024
Q2 		$2.75M Buy
+117,140
New +$3.95M ﹤0.01% 2223
2022
Q2 		– Sell
-6,765
Closed -$425K – 3471
2022
Q1 		$425K Buy
6,765
+12
+0.2% +$1.01K ﹤0.01% 3058
2021
Q4 		$653K Sell
6,753
-433
-6% -$68.3K ﹤0.01% 2998
2021
Q3 		$1.34M Sell
7,186
-185
-3% -$32.4K ﹤0.01% 2859
2021
Q2 		$1.28M Buy
7,371
+1,056
+17% +$192K ﹤0.01% 2914
2021
Q1 		$1.25M Sell
6,315
-303
-5% -$58.1K ﹤0.01% 2819
2020
Q4 		$1.3M Sell
6,618
-34
-0.5% -$7.05K ﹤0.01% 2704
2020
Q3 		$1.18M Sell
6,652
-1,684
-20% -$312K ﹤0.01% 2617
2020
Q2 		$1.93M Buy
8,336
+4,792
+135% +$913K ﹤0.01% 2353
2020
Q1 		$413K Sell
3,544
-14
-0.4% -$2.38K ﹤0.01% 2838
2019
Q4 		$680K Sell
3,558
-1,963
-36% -$385K ﹤0.01% 2821
2019
Q3 		$1.06M Sell
5,521
-35
-0.6% -$6.82K ﹤0.01% 2678
2019
Q2 		$951K Buy
+5,556
New +$960K ﹤0.01% 2766

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Nuveen's SYRE Position: Q2 2026 in Review

Nuveen increased its Spyre Therapeutics (SYRE) stake by 18% in Q2 2026, buying an estimated $1.99M and bringing the position to 181,105 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1406.

Nuveen first reported a position in SYRE in Q2 2019 and has held it in 21 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Nuveen held 181,105 shares of Spyre Therapeutics worth $16.1M as of Q2 2026.
  • Nuveen bought 27,206 Spyre Therapeutics shares in Q2 2026, an estimated $1.99M.
  • Spyre Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1406 holding.
  • Nuveen first reported a position in Spyre Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.